105 related articles for article (PubMed ID: 10436438)
1. Genotypic evolution in a quinolone-resistant Neisseria gonorrhoeae isolate from a patient with clinical failure of levofloxacin treatment.
Tanaka M; Sagiyama K; Haraoka M; Saika T; Kobayashi I; Naito S
Urol Int; 1999; 62(1):64-8. PubMed ID: 10436438
[TBL] [Abstract][Full Text] [Related]
2. Analysis of quinolone resistance mechanisms in a sparfloxacin-resistant clinical isolate of Neisseria gonorrhoeae.
Tanaka M; Nakayama H; Haraoka M; Nagafuji T; Saika T; Kobayashi I
Sex Transm Dis; 1998 Oct; 25(9):489-93. PubMed ID: 9800262
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone treatment failure in gonorrhea. Emergence of a Neisseria gonorrhoeae strain with enhanced resistance to fluoroquinolones.
Deguchi T; Saito I; Tanaka M; Sato K; Deguchi K; Yasuda M; Nakano M; Nishino Y; Kanematsu E; Ozeki S; Kawada Y
Sex Transm Dis; 1997 May; 24(5):247-50. PubMed ID: 9153731
[TBL] [Abstract][Full Text] [Related]
4. Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan.
Tanaka M; Takahashi K; Saika T; Kobayashi I; Ueno T; Kumazawa J
J Urol; 1998 Jun; 159(6):2215-9. PubMed ID: 9598572
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India.
Kulkarni S; Bala M; Sane S; Pandey S; Bhattacharya J; Risbud A
Int J Antimicrob Agents; 2012 Dec; 40(6):549-53. PubMed ID: 23063097
[TBL] [Abstract][Full Text] [Related]
6. Analysis of quinolone resistance mechanisms in Neisseria gonorrhoeae isolates in vitro.
Tanaka M; Sakuma S; Takahashi K; Nagahuzi T; Saika T; Kobayashi I; Kumazawa J
Sex Transm Infect; 1998 Feb; 74(1):59-62. PubMed ID: 9634306
[TBL] [Abstract][Full Text] [Related]
7. High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes.
Uthman A; Heller-Vitouch C; Stary A; Bilina A; Kuchinka-Koch A; Söltz-Szöts J; Tschachler E
Sex Transm Dis; 2004 Oct; 31(10):616-8. PubMed ID: 15389000
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Tanaka M; Tunoe H; Mochida O; Kanayama A; Saika T; Kobayashi I; Naito S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):109-13. PubMed ID: 11035242
[TBL] [Abstract][Full Text] [Related]
9. In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC.
Deguchi T; Yasuda M; Ishihara S; Takahashi Y; Okezaki E; Nagata O; Saito I; Kawada Y
J Antimicrob Chemother; 1997 Sep; 40(3):437-9. PubMed ID: 9338500
[TBL] [Abstract][Full Text] [Related]
10. Association between proline-requiring auxotype and fluoroquinolone resistance in Neisseria gonorrhoeae isolated in Japan.
Tsunoe H; Tanaka M; Mochida O; Nakayama H; Kanayama A; Saika T; Kobayashi I; Naito S
J Infect Chemother; 2001 Dec; 7(4):218-23. PubMed ID: 11810587
[TBL] [Abstract][Full Text] [Related]
11. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies.
Giles JA; Falconio J; Yuenger JD; Zenilman JM; Dan M; Bash MC
J Infect Dis; 2004 Jun; 189(11):2085-93. PubMed ID: 15143477
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of mutations in quinolone-resistance-determining regions and mtrR loci in polyclonal Neisseria gonorrhoeae isolates at a tertiary hospital in Southern Taiwan.
Chen PL; Lee HC; Yan JJ; Hsieh YH; Lee NY; Ko NY; Lin CW; Chang CM; Wu CJ; Lee CC; Ko WC
J Formos Med Assoc; 2010 Feb; 109(2):120-7. PubMed ID: 20206836
[TBL] [Abstract][Full Text] [Related]
13. Emergence of quinolone-resistant Neisseria gonorrhoeae in Pakistan.
Jabeen K; Khan E; Hasan R
Int J STD AIDS; 2006 Jan; 17(1):30-3. PubMed ID: 16409676
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda.
Bogaerts J; Tello WM; Akingeneye J; Mukantabana V; Van Dyck E; Piot P
Genitourin Med; 1993 Jun; 69(3):196-200. PubMed ID: 8335312
[TBL] [Abstract][Full Text] [Related]
15. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
16. Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group.
Tanaka M; Matsumoto T; Sakumoto M; Takahashi K; Saika T; Kabayashi I; Kumazawa J
Antimicrob Agents Chemother; 1998 Mar; 42(3):579-82. PubMed ID: 9517935
[TBL] [Abstract][Full Text] [Related]
17. Quinolone-resistant Neisseria gonorrhoeae in Hong Kong.
Kam KM; Wong PW; Cheung MM; Ho NK; Lo KK
Sex Transm Dis; 1996; 23(2):103-8. PubMed ID: 8919735
[TBL] [Abstract][Full Text] [Related]
18. Trends in antimicrobial resistance of Neisseria gonorrhoeae isolated from Korean patients from 2000 to 2006.
Lee H; Hong SG; Soe Y; Yong D; Jeong SH; Lee K; Chong Y
Sex Transm Dis; 2011 Nov; 38(11):1082-6. PubMed ID: 21992988
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial resistance of Neisseria gonorrhoeae in Japan, 1993-2002: continuous increasing of ciprofloxacin-resistant isolates.
Tanaka M; Nakayama H; Notomi T; Irie S; Tsunoda Y; Okadome A; Saika T; Kobayashi I
Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S15-22. PubMed ID: 15364300
[TBL] [Abstract][Full Text] [Related]
20. Mutation in DNA gyrase of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae.
Tanaka M; Otsuki M; Nishino T; Kobayashi I; Matsumoto T; Kumazawa J
Genitourin Med; 1996 Aug; 72(4):295-7. PubMed ID: 8976839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
